MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine receptor antagonists"

  • 2025 International Congress

    Drug-induced parkinsonism with resting tremor

    M. Nomoto, A. Watanabe (Imabari Ehime, Japan)

    Objective: Resting tremor might be developed by long-term treatment of dopamine receptor antagonists in cases of drug-induced parkinsonism Background: Resting tremor is one of the…
  • 2025 International Congress

    Increased Health Care Utilization in Children/Adolescents With Tourette Syndrome Treated With Dopamine D2 Receptor Antagonists: An Electronic Medical Records Database Analysis

    D. Isaacs, J. Swindle, F. Dabbous, G. Karkanias, S. Atkinson, F. Munschauer, F. Mazhar, C. Pettersson, S. Wanaski, T. Cunniff, K. Tomczak (Nashville, USA)

    Objective: To compare health care resource utilization (HCRU) in dopamine D2 receptor antagonist (D2RA)-exposed versus D2RA non-exposed individuals with Tourette syndrome (TS). Background: TS is…
  • 2025 International Congress

    Real-World Adverse Event Profile in Children and Adolescents With Tourette Syndrome Treated With Dopamine D2 Receptor Antagonists (D2RAs) Compared With Non-D2RAs

    K. Tomczak, J. Swindle, F. Dabbous, G. Karkanias, S. Atkinson, F. Munschauer, F. Mazhar, C. Pettersson, S. Wanaski, T. Cunniff, D. Isaacs (Bethesda, USA)

    Objective: To further explore the safety profile of dopamine D2 receptor antagonists (D2RAs) for Tourette syndrome (TS) in a community setting. Background: D2RAs (aripiprazole/haloperidol/pimozide) are…
  • 2025 International Congress

    Clinical Characteristics and Antipsychotic Medication Use in Pediatric Population Diagnosed With Tourette Syndrome

    K. Tomczak, J. Swindle, F. Dabbous, G. Karkanias, S. Atkinson, F. Munschauer, F. Mazhar, C. Pettersson, S. Wanaski, T. Cunniff, D. Isaacs (Boston, USA)

    Objective: To assess the clinical characteristics and rate of antipsychotic medication discontinuation in a pediatric cohort diagnosed with Tourette syndrome (TS). Background: It is estimated…
  • 2025 International Congress

    Scopolamine-induced Tardive Dyskinesia: A Case Report

    H. Deville, M. Christie (Houston, USA)

    Objective: To present a case of scopolamine-related Tardive Dyskinesia (TD) and review the documented anticholinergic-associated cases of TD and the underlying pathophysiology responsible for TD.…
  • 2025 International Congress

    Efficacy and safety of Rotigotine Extended-Release Microspheres in Early Parkinson’s Disease

    H. Sun, X. Dan, H. Chen, J. Feng, W. Wang, Q. Ye, Y. Liu, C. Liu, S. Chen, P. Chan (Beijing, China)

    Objective: To assess the efficacy and safety of Rotigotine extended-release microspheres (LY03003) in patients with early Parkinson's disease Background: Treatment that provides a continuous flow of…
  • 2024 International Congress

    Parkinson’s disease in a Special Population -Diagnosis and treatment of Parkinson’s disease in cases of psychiatric disorders treated with dopamine receptors antagonists-

    M. Nomoto, S. Oda, H. Doi (Imabari, Japan)

    Objective: We studied diagnosis and treatment of Parkinson’s disease in cases of psychiatric disorders treated with dopamine receptors antagonists for a long time. Background: Schizophrenia…
  • 2024 International Congress

    Initial Results After Launch of Best Practice Advisory for Contraindicated Agents in Parkinson’s Disease and Related disorders

    N. Shah, N. Chunga, K. Amodeo, I. Richard (Rochester, USA)

    Objective: To describe factors associated with triggering a best practice advisory (BPA) for dopamine-blocking agents (DBA) and report preliminary outcomes in hospitalized persons with Parkinson’s…
  • 2024 International Congress

    Rare Clinical Manifestation of Tardive Dyskinesia In Schizophrenic Patient on Quetiapine and Sertraline: A Case Report

    H. Oktaviani, A. Tiksnadi, D. Tunjungsari (Jakarta, Indonesia)

    Objective: To underscore the rarity of tardive dyskinesia manifestation in a schizophrenic patient, prescribed second-generation DRBA agents, quetiapine and SSRI sertraline. Background: Tardive dyskinesia is…
  • 2024 International Congress

    Safety and Tolerability of Ecopipam in Tourette Syndrome (TS) with Psychiatric Comorbidities.

    D. Gilbert, S. Atkinson, G. Karkanias, R. Munschauer, S. Wanaski, T. Cunniff (Cincinnati, USA)

    Objective: Evaluate the effect of ecopipam in children and adolescents with TS on measures of attention deficit disorder (ADHD), anxiety disorders (ANX), obsessive-compulsive disorder (OCD)…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley